ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS

Objective: Isatuximab (Isa, anti-CD38 monoclonal antibody) is approved in combination with carfilzomib (K) and dexamethasone (d), for relapsed multiple myeloma (MM) patients (pts) after ≥1 prior therapy. Final progression free survival (PFS) analysis after 2 years showed mPFS of 35.65 mo (Isa-Kd) vs...

Full description

Bibliographic Details
Published in:	Hematology, Transfusion and Cell Therapy
Main Authors:	Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137923002018

Similar Items

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
by: M. Turgut, et al.
Published: (2020-10-01)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
by: Marcelo Capra, et al.
Published: (2021-10-01)

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
by: Thomas Martin, et al.
Published: (2023-05-01)

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
by: Thomas Martin, et al.
Published: (2023-09-01)

LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
by: E Crusoe, et al.
Published: (2023-10-01)

Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis
by: Thierry Facon, et al.
Published: (2023-08-01)

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
by: Thierry Facon, et al.
Published: (2023-08-01)

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
by: Joshua Richter, et al.
Published: (2023-04-01)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
by: H. Quach, et al.
Published: (2022-06-01)

C063 | ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE VERSUS DARATUMUMAB-POMALIDOMIDE-DEXAMETHASONE IN PATIENTS PROGRESSING AFTER LENALIDOMIDE MAINTENANCE: AN ITALIAN REAL-LIFE STUDY
by: V. Ruocco, et al.
Published: (2025-09-01)

P173 | CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2025 DATA UPDATE
by: D. Derudas, et al.
Published: (2025-09-01)

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
by: David H. Vesole, et al.
Published: (2023-08-01)

Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
by: Paul G. Richardson, et al.
Published: (2024-02-01)

Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
by: Juan José Gil‐Fernández, et al.
Published: (2024-01-01)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
by: Philippe Moreau, et al.
Published: (2023-03-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
by: Giuseppe Mele, et al.
Published: (2018-01-01)

A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-2
by: PGR Md, et al.
Published: (2023-10-01)

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
by: Philippe Moreau, et al.
Published: (2023-08-01)

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
by: Meletios Dimopoulos, et al.
Published: (2018-04-01)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024-11-01)

P190 | ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION: A PROMISING SALVAGE STRATEGY FOR YOUNG, FIT PATIENTS WITH FIRST-RELAPSE MULTIPLE MYELOMA.
by: R. Della Pepa, et al.
Published: (2025-09-01)

B01 | ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (PHASE III ISKIA TRIAL)
by: F. Gay, et al.
Published: (2025-09-01)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
by: Carlyn Rose Tan, et al.
Published: (2023-07-01)

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
by: Dominik Dytfeld, et al.
Published: (2014-09-01)

Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience
by: Vera A. Zherebtsova, et al.
Published: (2021-07-01)

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
Published: (2023-03-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
by: Xavier Leleu, et al.
Published: (2023-02-01)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
by: Ioanna Barla, et al.
Published: (2022-11-01)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
by: Paul G. Richardson, et al.
Published: (2021-03-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Successful treatment with carfilzomib and dexamethasone for relapsed/refractory POEMS syndrome: a case report and review of literature
by: Shuang Yu, et al.
Published: (2025-06-01)

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient
by: Sarolta Bojtine Kovacs, et al.
Published: (2020-03-01)

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma
by: Elisabet E. Manasanch, et al.
Published: (2020-05-01)

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
by: Benjamin A. Derman, et al.
Published: (2024-05-01)

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
by: Tom Martin, et al.
Published: (2022-06-01)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
by: Roberto Mina, et al.
Published: (2020-02-01)

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
by: Kwee L. Yong, et al.
Published: (2021-04-01)